Community Trust & Investment Co. Boosts Holdings in Zoetis Inc. $ZTS

Community Trust & Investment Co. grew its position in Zoetis Inc. (NYSE:ZTS) by 1.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 110,394 shares of the company’s stock after buying an additional 1,659 shares during the period. Community Trust & Investment Co.’s holdings in Zoetis were worth $17,216,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC boosted its position in shares of Zoetis by 2.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 152,469 shares of the company’s stock worth $24,270,000 after purchasing an additional 4,167 shares during the period. Alecta Tjanstepension Omsesidigt boosted its position in shares of Zoetis by 24.5% during the 2nd quarter. Alecta Tjanstepension Omsesidigt now owns 709,900 shares of the company’s stock worth $110,659,000 after purchasing an additional 139,500 shares during the period. Secure Asset Management LLC boosted its position in shares of Zoetis by 2.9% during the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after purchasing an additional 68 shares during the period. Baader Bank Aktiengesellschaft boosted its position in shares of Zoetis by 43.5% during the 2nd quarter. Baader Bank Aktiengesellschaft now owns 3,590 shares of the company’s stock worth $540,000 after purchasing an additional 1,089 shares during the period. Finally, Sivia Capital Partners LLC boosted its position in shares of Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.5%

ZTS stock opened at $146.72 on Thursday. The stock has a market cap of $65.02 billion, a PE ratio of 25.25, a price-to-earnings-growth ratio of 2.37 and a beta of 0.89. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The firm’s 50-day simple moving average is $151.67 and its 200 day simple moving average is $156.92. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analyst Weigh In

ZTS has been the subject of several recent research reports. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Argus restated a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Piper Sandler raised their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.